Abstract:Abstract Abstract 4507 Adoptive immunotherapy with antigen-specific T cells can be effective in the treatment of melanoma, as well as chronic myeloid leukemia (CML). However, to obtain sufficient antigen-specific T cells for treatment, T cells have to be cultured for several weeks in vitro, and in vitro expanding T cells is difficult to control. Alternatively, transfer of T cell receptors (TCR) with defined antigen specificity into recipient T cells may be simply generation of antigen-specific T cells. The TCR-transferred T cells have been demonstrated to be functionally active in mouse models. TCR gene transfer is shown as a safe strategy, but appears limited by an objective response rate of 12%. It is adversely affected by newly formed TCRαβ heterodimers comprising exogenous and endogenous TCR chains that dilute expression of transgenic TCRαβ and are potentially self-reactive or by reduced expression of CD3ζ which has been found to be decreased in CD4+ and CD8+ T cells isolated from the tumor site or from the peripheral circulation of patients with cancer. Our previous study has identified the oligoclonal Vβ21 with different oligoclonal Vα partner in peripheral blood mononuclear cells (PBMCs) from patients with CML.In the present study, full-length gene sequences of oligoclonal Vβ21, Vα13 and Vα18 had been obtained from a case with CML using PCR, then the TCR genes were fused with whole human CD3ζ chain gene respectively. Each of chimeric Vα18-CD3ζ and Vα13-CD3ζ pairing Vβ21-CD3ζ was cloned into PIRES plasmid respectivelyto construct two recombinant plasmids Vα13-CD3ζ-IRES-Vβ21-CD3ζ and Vα18-CD3ζ-IRES-Vβ21-CD3ζ. Subsequently, their sequences were confirmed by restriction enzyme digestionanalysis and nucleotide sequencing. Each recombinant plasmids was transfected into K293 cells and Molt-4 cellsusing LipofectamineTM2000 or nucleofection respectively. The mRNA expression of TCR Vα18, Vα13, Vβ21 and CD3ζ chain genes in transfected cells were detected by RT-PCR and real-timePCR. The erpression of TCR Vβ21 chain in transfected cells was confiomred by staining with FITC-conjugated anti-TCR Vβ21.3 mAb using laser confocal microscopy(LCM) and flow cytometry (FCM) analysis. The expression of CD3ζ chain in transfected K293 and Molt-4 cells were detected by western-blot using anti human CD3ζ mAb. The results showed that two kindsof eukaryotic expression plasmids encoding chimeric TCR Vα13-CD3ζ/Vβ21-CD3ζ and Vα18-CD3ζ/Vβ21-CD3ζ specific for CMLwere constructed successfully and could express the relevant proteins well in vitro after transfecting both K293 cells and Molt-4cells. Farther studies will be performed to transfect the chimeric TCR Vα-CD3ζ/Vβ-CD3ζ plasmids in recipient T cells to detect the specific cytotoxicity. Chimeric TCR that encompasses whole human CD3ζ may be a dual strategy that might enhance the efficacy and safety of TCR gene transfer and improve T cell immunodeficiency induced impaired expression of the CD3ζ chain, farther study is required to confirm the suggestion. Disclosures: Zha: The study was supported by grants from Key project of Natural Science Foundation of Guangdong province, China (No. 05103293 and No. 9251063201000001) : Research Funding. Yin:The study was supported by grants from Key project of Natural Science Foundation of Guangdong province, China (No. 05103293 and No. 9251063201000001) : Research Funding. Chen:The study was supported by grants from Key project of Natural Science Foundation of Guangdong province, China (No. 05103293 and No. 9251063201000001) : Research Funding. Yang:The study was supported by grants from Key project of Natural Science Foundation of Guangdong province, China (No. 05103293 and No. 9251063201000001) : Research Funding. Zhou:The study was supported by grants from Key project of Natural Science Foundation of Guangdong province, China (No. 05103293 and No. 9251063201000001) : Research Funding. Li:The study was supported by grants from Key project of Natural Science Foundation of Guangdong province, China (No. 05103293 and No. 9251063201000001) : Research Funding.

Increasing TCR Zeta Expression and Maintaining the Clonality of T Cells from AML Patients after IL-2, IL-7 and IL-12 Induction

Enhancement of the TCRζ expression, polyclonal expansion, and activation of t cells from patients with acute myeloid leukemia after IL-2, IL-7, and IL-12 induction

Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia

Upregulated TCR Zeta and Improved the IFN-γ Secretion and Cytotoxicity in T Cell from Patients with AML after IL-2, IL-7 and IL-12 Stimulation

UP-regulated TCRζ Improves Cytokine Secretion in T Cells from Patients with AML

Upregulated Tcr Zeta Enhances Interleukin-2 Production In T-Cells From Patients With Cml

Upregulation of TCRζ Chain Overcome T Cell Immunodeficiency in Patients with Chronic Myeloid Leukemia

Upregulated TCRζ Enhances Interleukin-2 Production in T-Cells from Patients with CML

Tcr Zeta Chain Expression in T Cells from Patients with Cml

Dysexpression of TCRζ Related Genes in the Patients with Chronic Myeloid Leukemia

Expression Feature of Elf-1, Zap-70 and FcεR Ⅰγin T Cells from Acute Myeloid Leukemia Patients with TCR Ζ Deficiency

Increasing Frequency of T Cell Immunosuppressive Receptor Expression in Cd4+And Cd8+T Cells May Related to T Cell Exhaustion and Immunosuppression in Patients with Aml

Construction and Expression of Eukaryotic Expression Plasmids Containing CML-Associated Antigen Specific TCRs That Fused CD3ζ Chain Gene.

The Feature of Tcr Zeta Gene in Cd4+And Cd8+T Cells in Patients with Cml

[Study on Clonal Proliferation of TCR Vbeta Subfamily T Cells Induced by AML-M(2a) Cells in Vivo and in Vitro].

Deficiency of Cd3gamma, Delta, Epsilon, and Zeta Expression in T Cells from Aml Patients

Clonal Expansion of Bone Marrow CD8+ T Cells in Acute Myeloid Leukemia Patients at New Diagnosis and Post Chemotherapy

[Changes of T-cell Clonality after Induction-Cultivation of Peripheral T Lymphocytes in Adoptive Immunotherapy for Leukemias].

Characteristics of the Tcr Vbeta Repertoire and Identical Clonally Expanded T Cells in Chronic Myeloid Leukemia Patients in Advanced Phase with Abl Mutations

Oligoclonal Expansion of TCR Vδ T Cells May Be a Potential Immune Biomarker for AML Outcome

Clonal Expansion and Specific Cytotoxicity of TCR Vβ Subfamily T Cells Induced by AML-M2a Cells